Naftopidil for the treatment of urinary symptoms in patients with benign prostatic hyperplasia

Naftopidil, approved only in Japan, is an α1-adrenergic receptor antagonist (α1-blocker) used to treat lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH). Different from tamsulosin hydrochloride and silodosin, in that it has higher and extremely higher affinity resp...

Descripción completa

Detalles Bibliográficos
Autor principal: Masumori, Naoya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2011
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3132093/
https://www.ncbi.nlm.nih.gov/pubmed/21753885
http://dx.doi.org/10.2147/TCRM.S13883

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3132093/
https://www.ncbi.nlm.nih.gov/pubmed/21753885
http://dx.doi.org/10.2147/TCRM.S13883

Ejemplares similares